Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

PURPOSE: Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated with platinum and anti–programmed death 1 or anti–programmed death ligand 1 (PD-1/L1) therapy. Enfortumab vedotin is an antibody–dr...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Oncol
Главные авторы: Rosenberg, Jonathan E., O’Donnell, Peter H., Balar, Arjun V., McGregor, Bradley A., Heath, Elisabeth I., Yu, Evan Y., Galsky, Matthew D., Hahn, Noah M., Gartner, Elaina M., Pinelli, Juan M., Liang, Shang-Ying, Melhem-Bertrandt, Amal, Petrylak, Daniel P.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2019
Предметы:
RAPID COMMUNICATION
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784850/
https://ncbi.nlm.nih.gov/pubmed/31356140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01140
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы